-
公开(公告)号:US08883799B2
公开(公告)日:2014-11-11
申请号:US13326524
申请日:2011-12-15
申请人: Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
发明人: Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC分类号: C07D471/04 , C07D471/22 , C07D487/04 , C07D413/00 , C07D265/00 , C07D498/00 , A61K31/535 , C07D498/14 , C07D491/14 , C07D495/14 , C07D487/14
CPC分类号: C07D498/22 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/3955 , A61K2039/505 , C07D471/14 , C07D471/22 , C07D487/14 , C07D491/14 , C07D491/147 , C07D495/14 , C07D498/14 , C07D498/20 , C07K16/22 , C07K2317/24
摘要: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
摘要翻译: 描述了具有抗癌活性,抗炎活性或免疫调节特性,更具体地与PI3激酶调节或抑制活性的式I的三环PI3k抑制剂化合物。 描述了使用式I的三环PI3K抑制剂化合物用于体外,原位和体内诊断或治疗哺乳动物细胞,生物体或相关病理条件的方法。 式I化合物包括立体异构体,几何异构体,互变异构体及其药学上可接受的盐。 虚线表示可选的双键,至少一条虚线是双键。 取代基如所述。
-
公开(公告)号:US20120171199A1
公开(公告)日:2012-07-05
申请号:US13326524
申请日:2011-12-15
申请人: Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
发明人: Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC分类号: A61K31/5383 , C07D491/147 , C07D498/14 , C07D487/14 , C07D498/22 , A61K31/5386 , A61K31/5377 , A61P35/00 , A61P29/00 , A61P37/02 , A61P25/00 , A61P9/00 , A61P1/16 , A61P31/12 , A61P7/00 , A61P3/10 , A61P37/04 , A61P35/02 , C07D471/14 , C07D495/14 , A61K39/395
CPC分类号: C07D498/22 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/3955 , A61K2039/505 , C07D471/14 , C07D471/22 , C07D487/14 , C07D491/14 , C07D491/147 , C07D495/14 , C07D498/14 , C07D498/20 , C07K16/22 , C07K2317/24
摘要: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
摘要翻译: 描述了具有抗癌活性,抗炎活性或免疫调节特性,更具体地与PI3激酶调节或抑制活性的式I的三环PI3k抑制剂化合物。 描述了使用式I的三环PI3K抑制剂化合物用于体外,原位和体内诊断或治疗哺乳动物细胞,生物体或相关病理条件的方法。 式I化合物包括立体异构体,几何异构体,互变异构体及其药学上可接受的盐。 虚线表示可选的双键,至少一条虚线是双键。 取代基如所述。
-